BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB(4) receptor is critically associated with the phenotypes of TNBC cells, including invasion, metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, JaeIn, Jang, Jae-Hyun, Park, Geun-Soo, Chung, Yunro, You, Hye Jin, Kim, Jae-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2018
Materias:
Invited Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130834/
https://www.ncbi.nlm.nih.gov/pubmed/29898809
http://dx.doi.org/10.5483/BMBRep.2018.51.8.127
_version_ 1783354015785943040
author Park, JaeIn
Jang, Jae-Hyun
Park, Geun-Soo
Chung, Yunro
You, Hye Jin
Kim, Jae-Hong
author_facet Park, JaeIn
Jang, Jae-Hyun
Park, Geun-Soo
Chung, Yunro
You, Hye Jin
Kim, Jae-Hong
author_sort Park, JaeIn
collection PubMed
description Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB(4) receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.
format Online
Article
Text
id pubmed-6130834
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Korean Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-61308342018-09-12 BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer Park, JaeIn Jang, Jae-Hyun Park, Geun-Soo Chung, Yunro You, Hye Jin Kim, Jae-Hong BMB Rep Invited Mini Review Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB(4) receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC. Korean Society for Biochemistry and Molecular Biology 2018-08 2018-08-31 /pmc/articles/PMC6130834/ /pubmed/29898809 http://dx.doi.org/10.5483/BMBRep.2018.51.8.127 Text en Copyright © 2018 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Invited Mini Review
Park, JaeIn
Jang, Jae-Hyun
Park, Geun-Soo
Chung, Yunro
You, Hye Jin
Kim, Jae-Hong
BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
title BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
title_full BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
title_fullStr BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
title_full_unstemmed BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
title_short BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
title_sort blt2, a leukotriene b(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
topic Invited Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130834/
https://www.ncbi.nlm.nih.gov/pubmed/29898809
http://dx.doi.org/10.5483/BMBRep.2018.51.8.127
work_keys_str_mv AT parkjaein blt2aleukotrieneb4receptor2asanovelprognosticbiomarkeroftriplenegativebreastcancer
AT jangjaehyun blt2aleukotrieneb4receptor2asanovelprognosticbiomarkeroftriplenegativebreastcancer
AT parkgeunsoo blt2aleukotrieneb4receptor2asanovelprognosticbiomarkeroftriplenegativebreastcancer
AT chungyunro blt2aleukotrieneb4receptor2asanovelprognosticbiomarkeroftriplenegativebreastcancer
AT youhyejin blt2aleukotrieneb4receptor2asanovelprognosticbiomarkeroftriplenegativebreastcancer
AT kimjaehong blt2aleukotrieneb4receptor2asanovelprognosticbiomarkeroftriplenegativebreastcancer

Ejemplares similares